

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

| | | | | | | | | | | | | | |
|---|--|---------------------------|--|--------------------|--|-----------------------------|-------------------------|-----------------------|--|----------------------|--|-------------------------------|----------|
| <p>Substitute for form 1449A/PTO</p> <h2 style="text-align: center; margin: 10px 0;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center; font-size: small;">(use as many sheets as necessary) Sheet 1 of 3</p> | <table border="1" style="width: 100%; border-collapse: collapse;"> <tr><td colspan="2">Application Number</td></tr> <tr><td colspan="2">Filing Date</td></tr> <tr><td>First Named Inventor</td><td>M. Bogenstaetter et al.</td></tr> <tr><td colspan="2">Group Art Unit</td></tr> <tr><td colspan="2">Examiner Name</td></tr> <tr><td>Attorney Docket Number</td><td>ORT-1614</td></tr> </table> | Application Number | | Filing Date | | First Named Inventor | M. Bogenstaetter et al. | Group Art Unit | | Examiner Name | | Attorney Docket Number | ORT-1614 |
| Application Number | | | | | | | | | | | | | |
| Filing Date | | | | | | | | | | | | | |
| First Named Inventor | M. Bogenstaetter et al. | | | | | | | | | | | | |
| Group Art Unit | | | | | | | | | | | | | |
| Examiner Name | | | | | | | | | | | | | |
| Attorney Docket Number | ORT-1614 | | | | | | | | | | | | |

U.S. PATENT DOCUMENTS

| Examiner Initials | Cite No. ¹ | U.S. Patent Document | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document mm-dd-yyyy | Pages, Columns, Lines, where relevant passages or relevant figures appear |
|----------------------|--------------------------|----------------------|--------------------------------------|--|--|---|
| | | Number | Kind Code ² (if known) | | | |
| KH ↓ | | 5,217,986 | | Pomponi, S.A. et al. | 06-08-1993 | |
| | | 5,352,707 | | Pompni et al. | 10-04-1994 | |
| | | 5,869,479 | | Krautner, W. et al. | 02-09-1999 | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |

FOREIGN PATENT DOCUMENTS

| Examiner Initials | Cite No. ¹ | Foreign Patent Document | | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document mm-dd-yyyy | Pages, Columns, Lines, where relevant passages or relevant figures appear | T ⁶ |
|----------------------|--------------------------|-------------------------|---------------------|------------------------|--|--|--|----------------|
| | | Office ³ | Number ⁴ | Kind Code ⁵ | | | | |
| KH | | EP | 0 978 512 | A1 | Societe Civile Bioprojet | 02-09-2000 | | |
| KH | | WO | 99/42458 | | James Black Foundation Limited | 08-26-1999 | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |

| | | |
|---------------------|------------------|-----------|
| Examiner Signature: | Date Considered: | 3/20/2007 |
|---------------------|------------------|-----------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 3.

Application Number

Filing Date

First Named Inventor

M. Bogenstaetter et al.

Group Art Unit

Examiner Name

Attorney Docket Number

ORT-1614

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

| Examiner's Initials* | Cite No. ¹ | Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | T ² |
|----------------------|-----------------------|--|----------------|
| K4 | | ARRANG, J.M. et al.; "Auto-inhibition of brain histamine release mediated by a novel class (h3) of histamine receptor" Nature; April 1983; 302:832-837 | |
| | | ASH, A.S.F. et al.; "Receptors Mediating Some Actions of Histamine"; Br. J. Pharmac. Chemother.; 1966 27:427-439 | |
| | | BARNES, J.C. et al.; "The selective Histamine H3 Receptor Antagonist Thioperamide Improves Cognition and Enhances Hippocampal Acetylcholine Release in vivo"; Soc. Neurosci. Abstr.; 1993 19:1813 | |
| | | Bloworld Today, March 2, 1999, page 3 | |
| | | BLACK, J.W. et al.; "Definition and Antagonism of Histamine H2-receptors"; Nature; April 1972; 236:385-390 | |
| | | DING, Y. S. et al. "Synthesis of High Specific Activity (+)- and (-)-[6- ¹⁸ F]Fluoronorepinephrine via the Nucleophilic Aromatic Substitution Reaction"; J. Med. Chem. (1991) 34:767-771 | |
| | | GANELLIN, C.R. et al.; "Synthesis of Potent Non-Imidazole Histamine H3-Receptor Antagonists"; Arch. Pharm. Pharm. Med. Chem. (Weinheim, Ger.); 1998 331:395-404 | |
| | | GARBAG, M. et al.; "S-[2-(4-Imidazolyl)ethyl]isothiourea, a Highly Specific and Potent Histamine H3 Receptor Agonist"; J. Pharmacol. Exp. Ther.; 1992; 263(1):304-310 | |
| | | GILATECH, INC.; "Gilatech's first drug candidate begins phase I human clinical trials"; Gilatech Inc. Press Release; November 5, 1998 | |
| | | ICHINOSE, M. et al.; "Histamine H3-receptors modulate nonadrenergic noncholinergic neural bronchoconstriction in guinea-pig in vivo"; P.J. Eur. J. Pharmacol.; 1989; 174:49-55 | |
| | | IMAMURA, M. et al.; "Unmasking of Activated Histamine H3-Receptors in Myocardial Ischemia: Their Role as Regulators of Exocytotic Norepinephrine Release 1,2"; J. Pharmacol. Exp. Ther.; 1994; 271(3):1259-1266 | |
| | | JONES, R.G. "Studies on Imidazoles. II. The Synthesis of 5-Imidazolecarboxylates from Glycine and Substituted Glycine Esters. J. Am. Chem. Soc. (1949) 71:644-647 | |
| | | KORTE, A. et al.; "Characterization and Tissue Distribution of H3 Histamine Receptors in Guinea Pigs by Na-Methylhistamine"; Biochem. Biophys. Res. Commun.; May 1990; 168(3):979-986 | |
| | | KRAUSE, M. et al.; "The Histamine H3 Receptor-A Target for New Drugs"; Leurs, R.; Timmerman, H. (Eds.); Elsevier; 1998; 175-196 | |
| | | LEURS, R. et al.; "The medicinal chemistry and therapeutic potentials of ligands of the histamine h3 receptor" Prog. Drug. Res.; 1995; 45:107-165 | |
| | | LIN, Jian-Sheng et al. "Involvement of histaminergic neurons in arousal mechanisms demonstrated with H3-receptor ligands in the cat"; Brain Res.; 1990; 523:325-330 | |
| | | LINNEY, I.D. et al.; "Design, Synthesis, and Structure-Activity Relationships of Novel Non-Imidazole Histamine H3 Receptor Antagonists"; J. Med. Chem.; 2000; 43:2382-2370 | |
| | | LOVENBERG, T.W. et al.; "Cloning and Functional Expression of the Human Histamine H3 Receptor"; Mol. Pharmacol.; 1999 55:1101-1107 | |
| | | LOVENBERG, T.W. et al. "Cloning of Rat Histamine H3 Receptor Reveals Distinct Species Pharmacological Profiles. J. Pharmacol. Exp. Ther. (2000) 293:771-778 | |
| | | MACHIDORI, H. et al.; "Zucker obese rats: defect in brain histamine control of feeding"; Brain Res.; 1992; 590:180-186 | |
| | | MCLEOD, R.L. et al.; "Antimigraine and Sedative Activity of SCH 50971: A Novel Orally-Active Histamine H3 Receptor Agonist"; Soc. Neurosci. Abstr.; 1996; 22:2010 | |
| | | MONTI, J.M. et al.; "Effects of selective activation or blockade of the histamine h3 receptor on sleep and wakefulness"; Eur. J. Pharmacol.; 1991; 205:283-287 | |
| | | MORISSET, S. et al.; "High constitutive activity of native H3 receptors regulates histamine neurons in brain"; Nature; Dec.; 2000; 408:860-864 | |
| | | ODA, Tamaki et al.; "Molecular Cloning and characterization of a Novel Type of Histamine Receptor Preferentially Expressed in Leukocytes"; J. Biol. Chem.; Nov. 2000; 275(47):36781-36786 | |
| | | PANULA, P. et al.; "Significant Changes in the Human Brain Histaminergic System in Alzheimer's Disease" Soc. Neurosci. Abstr.; 1995; 21:1977 | |
| | | PHELPS, M.E. "Positron Emission Tomography Provides Molecular Imaging of Biological Processes." Proc. Natl. Acad. Sci. (2000) 97:9228-9233 | |
| | | PHILLIPS, J.G.; ALI, S.M. "In the Histamine H3 Receptor-A Target for New Drugs" Leurs, R.; Timmerman, H. (Eds.) Elsevier (1998) 197-222 | |

Examiner
Signature

A M / h

Date
Considered

3/20/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

Substitute for form 1449A/PTO

(use as many sheets as necessary)

Sheet 3 of 3

| |
|----------|
| ORT-1614 |
|----------|

[illegible]

**Examiner
Signature**

Date
Considered

3/20/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.